A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men

NCT06631430 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-06-18

No results posted yet for this study

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3810477 in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

BI 3810477

BI 3810477 formulation A

DRUG

BI 3810477

BI 3810477 formulation B

DRUG

Placebo

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2025-06-12
Completion
2025-06-12

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06631430 on ClinicalTrials.gov